Genmab Capex To Depreciation from 2010 to 2024
| GMAB Stock | USD 20.75 0.80 3.71% |
Capex To Depreciation | First Reported 2010-12-31 | Previous Quarter 1.14984709 | Current Value 1.08 | Quarterly Volatility 1.83416795 |
Check Genmab AS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab AS's main balance sheet or income statement drivers, such as Depreciation And Amortization of 252 M, Interest Expense of 16.6 M or Selling General Administrative of 3.5 B, as well as many indicators such as Price To Sales Ratio of 8.12, Dividend Yield of 0.0 or PTB Ratio of 5.55. Genmab financial statements analysis is a perfect complement when working with Genmab AS Valuation or Volatility modules.
Genmab | Capex To Depreciation |
Latest Genmab AS's Capex To Depreciation Growth Pattern
Below is the plot of the Capex To Depreciation of Genmab AS over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Genmab AS's Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genmab AS's overall financial position and show how it may be relating to other accounts over time.
| Capex To Depreciation | 10 Years Trend |
|
Capex To Depreciation |
| Timeline |
Genmab Capex To Depreciation Regression Statistics
| Arithmetic Mean | 1.87 | |
| Geometric Mean | 1.34 | |
| Coefficient Of Variation | 97.94 | |
| Mean Deviation | 1.39 | |
| Median | 1.08 | |
| Standard Deviation | 1.83 | |
| Sample Variance | 3.36 | |
| Range | 5.6392 | |
| R-Value | (0.16) | |
| Mean Square Error | 3.53 | |
| R-Squared | 0.03 | |
| Significance | 0.57 | |
| Slope | (0.07) | |
| Total Sum of Squares | 47.10 |
Genmab Capex To Depreciation History
About Genmab AS Financial Statements
Genmab AS stakeholders use historical fundamental indicators, such as Genmab AS's Capex To Depreciation, to determine how well the company is positioned to perform in the future. Although Genmab AS investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genmab AS's assets and liabilities are reflected in the revenues and expenses on Genmab AS's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genmab AS. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capex To Depreciation | 1.15 | 1.08 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out the analysis of Genmab AS Correlation against competitors. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.